Aclaris Therapeutics Inc (NASDAQ:ACRS)
| 14.43 Delayed Data As of Jun 24 |  -1.42 / -8.96%Today’s Change | 9.26 Today|||52-Week Range 19.97 | -0.76% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $960.1M |
Company Description
Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments. The Therapeutics segment focuses on identifying, developing, and commercializing different therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.
Contact Information
Aclaris Therapeutics, Inc. 640 Lee Road Wayne Pennsylvania 19087 |
Employees
Shareholders
| Other institutional | 56.27% |
| Individual stakeholders | 38.51% |
| Mutual fund holders | 18.74% |
Top Executives
| Neal S. Walker | President, Chief Executive Officer & Director |
| Frank Ruffo | Chief Financial Officer, Secretary & Treasurer |
| Joseph B. Monahan | Chief Scientific Officer |
| Monica Salamea | Vice President-Clinical Operations |
| James Loerop | Chief Business Officer |
